I-Mab gains Chinese rights to MorphoSys' MOR210

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) granted I-Mab Biopharma (Shanghai, China) exclusive rights to develop and commercialize preclinical compound MOR210 in China, including Hong Kong and Macau, Taiwan and South Korea.

I-Mab will be responsible for all global development of the antibody, and in exchange for a "successful clinical proof-of-concept study," is eligible for low, single-digit tiered royalties and a tiered percentage of licensing revenue...